Advertisement

Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review

  • Silvia MorbelliEmail author
  • Selene Capitanio
  • Luca Guerra
  • Luigi Rigacci
Systematic Review
  • 16 Downloads
Part of the following topical collections:
  1. Lymphatic and hematological system

Abstract

Purpose

We aimed to systematically review studies addressing the value of baseline FDG PET as predictive biomarker for response to RIT in patients with NHL.

Methods

We searched (last update: March 2019) the databases PubMed, PMC, Google Scholar and Medline using both as text and as MeSH (Medical Subject Headings) terms the following: “positron emission tomography—PET”, “PET/CT”, “FDG”, “18F-fluorodeoxyglucose”, and “radioimmunotherapy”, ‘90Y-ibritumomab tiuxetan” and “non-Hodgkin lymphoma” and “follicular lymphoma”. Among all the retrieved articles, we selected only those specifically analyzing role, predictive and overall value of pretreatment FDG PET in patients with NHL submitted to RIT.

Results

The initial search retrieved seventy articles, however, only eight specifically analyzed the predictive value of pretreatment FDG PET in patients with NHL submitted to RIT and were thus discussed. Eight studies in 254 patients evaluated the role of FDG PET as a predictor of response prior to RIT. Despite several methodological issues, patients- and lesion-based analyses carried out to-date seem to suggest a relevant prognostic role of both morphological computed tomography and metabolic imaging.

Conclusions

Although it is still not possible to specifically define the best PET-based predictor (i.e. SUVmax, TLG, MTV), FDG-PET is a promising tool for a more accurate and individualized selection of NHL patients candidates to RIT. The availability of FDG PET examinations in homogenous group of patients included in already completed clinical trials might be used in the next future also to specifically assess the prognostic value of baseline FDG PET in patients treated with RIT based on the study design.

Keywords

Positron emission tomography 18F-FDG Radioimmunotherapy 90Y-ibritumomab tiuxetan 

Notes

Author contributions

SM and SC: literature search and review, manuscript writing. LG and LR manuscript writing and editing.

Funding

This study was not funded by grants.

Compliance with ethical standards

Conflict of interest

SM received speaker honoraria from General Electric and Eli-Lilly. The other authors declare no conflict of interest.

Statement of human rights

As a review this statement is not mandatory.

References

  1. 1.
    Kapadia NS, Engles JM, Wahl RL (2008) In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med 49(4):674–678CrossRefGoogle Scholar
  2. 2.
    Dillman RO (2002) Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 20(16):3545–3557CrossRefGoogle Scholar
  3. 3.
    Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A et al (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 17(12):3793–3803CrossRefGoogle Scholar
  4. 4.
    Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99(12):4336–4342CrossRefGoogle Scholar
  5. 5.
    Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN et al (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 20(15):3262–3269CrossRefGoogle Scholar
  6. 6.
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463CrossRefGoogle Scholar
  7. 7.
    Rizzieri D (2016) Zevalin(®) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol 105:5–17CrossRefGoogle Scholar
  8. 8.
    Mondello P, Cuzzocrea S, Navarra M, Mian M (2016) 90Y-ibritumomab tiuxetan: a nearly forgotten opportunity. Oncotarget 7(7):7597–7609CrossRefGoogle Scholar
  9. 9.
    Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51CrossRefGoogle Scholar
  10. 10.
    Lindén O, Tennvall J, Cavallin-Ståhl E, Darte L, Garkavij M, Lindner K (1999) Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. J Clin Cancer Res 5(10 Suppl):3287s–3291sGoogle Scholar
  11. 11.
    Hohloch K, Lankeit HK, Zinzani PL, Scholz CW, Lorsbach M, Windemuth-Kieselbach C et al (2014) Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. Eur J Nucl Med Mol Imaging 41(8):1585–1592CrossRefGoogle Scholar
  12. 12.
    White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL et al (1996) Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 87(9):3640–3649Google Scholar
  13. 13.
    Buchegger F, Press OW (2011) Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma. EJNMMI Res 1(1):7CrossRefGoogle Scholar
  14. 14.
    Multani P (2002) Development of radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma. Int J Hematol 76(5):401–410CrossRefGoogle Scholar
  15. 15.
    Illidge TM (2010) Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date. J Clin Oncol 28:2944–2946CrossRefGoogle Scholar
  16. 16.
    Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL (2010) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of US medical oncologists and hematologists. J Nucl Med 51(6):987–994CrossRefGoogle Scholar
  17. 17.
    Garber K (2007) Users fear that lymphoma drugs will disappear. J Natl Cancer Inst 99(7):498–499CrossRefGoogle Scholar
  18. 18.
    Press OW (2008) Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. J Clin Oncol 26(32):5147–5150CrossRefGoogle Scholar
  19. 19.
    Eskian M, Khorasanizadeh M, Kraeber-Bodere F, Rezaei N (2016) Radioimmunotherapy in non-Hodgkin lymphoma: prediction and assessment of response. Crit Rev Oncol Hematol 107:182–189CrossRefGoogle Scholar
  20. 20.
    Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P (2005) The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med 46(11):1812–1818Google Scholar
  21. 21.
    Kaneko K, Choi I, Nakagawa M, Shinozaki K, Uike N (2014) Does tumoral (111)In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing (90)Y-ibritumomab radioimmunotherapy? Eur Radiol 24(12):3191–3198CrossRefGoogle Scholar
  22. 22.
    Hanaoka K, Hosono M, Tatsumi Y, Ishii K, Im SW, Tsuchiya N et al (2015) Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma. EJNMMI Res 5:10CrossRefGoogle Scholar
  23. 23.
    Nowosinska E, Chan PS, Buscombe JR (2018) Use of 18F FDG PET and the short temporal response of Hodgkin’s disease to RIT. World J Nucl Med 17(3):171–177CrossRefGoogle Scholar
  24. 24.
    Takahashi M, Momose T, Koyama K, Ichikawa M, Kurokawa M, Ohtomo K (2014) Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy. Sci World J 2014:368947Google Scholar
  25. 25.
    Storto G, De Renzo A, Pellegrino T, Perna F, De Falco T, Erra P et al (2010) Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Radiology 254(1):245–252CrossRefGoogle Scholar
  26. 26.
    Gregory SA (2003) Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol 30(Suppl. 17):17–22CrossRefGoogle Scholar
  27. 27.
    Tsukamoto N, Yokohama A, Higuchi T, Mitsui T, Koiso H, Takizawa M et al (2019) Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy. Int J Hematol 109(1):91–97CrossRefGoogle Scholar
  28. 28.
    Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A et al (2017) Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica 102(2):356–363CrossRefGoogle Scholar
  29. 29.
    Grgic A, Nestle U, Scheidhauer K, Puskas C, Ballek E, Hohloch K (2011) Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin’s lymphoma. Nuklearmedizin 50(1):39–47CrossRefGoogle Scholar
  30. 30.
    Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F et al (2010) FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol 21(9):1877–1883CrossRefGoogle Scholar
  31. 31.
    Lopci E, Santi I, Tani M, Maffione AM, Montini G, Castellucci P et al (2010) FDG PET and 90Y-ibritumomab tiuxetan in patients with follicular lymphoma. Q J Nucl Med Mol Imaging 54(4):436–441Google Scholar
  32. 32.
    Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangère T, Steinling M et al (2010) Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37(3):494–504CrossRefGoogle Scholar
  33. 33.
    Lim I, Park JY, Kang HJ, Hwang JP, Lee SS, Kim KM et al (2013) Prognostic significance of pretreatment 18F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma treated by radioimmunotherapy using 131I-rituximab. Acta Haematol 130(2):74–82CrossRefGoogle Scholar
  34. 34.
    Jacene HA, Filice R, Kasecamp W, Wahl RL (2009) 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 50(1):8–17CrossRefGoogle Scholar
  35. 35.
    Kitajima K, Okada M, Kashiwagi T, Yoshihara K, Tokugawa T, Sawada A et al (2019) Early evaluation of tumor response to (90)Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT? Eur Radiol.  https://doi.org/10.1007/s00330-019-06134-7 Google Scholar
  36. 36.
    Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA et al (2014) Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica 99(11):1738–1745CrossRefGoogle Scholar
  37. 37.
    Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T et al (2017) Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-Lilotomab satetraxetan. J Nucl Med 58(1):48–54CrossRefGoogle Scholar
  38. 38.
    Green DJ, O’Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK et al (2017) CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood 131:611–662CrossRefGoogle Scholar
  39. 39.
    Janik JE, Morris JC, O’Mahony D, Pittaluga S, Jaffe ES, Redon CE et al (2015) 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma. Proc Natl Acad Sci USA 112(42):13045–13050CrossRefGoogle Scholar
  40. 40.
    Lapa C, Hänscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA et al (2019) Feasibility of CXCR43-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med 60(1):60–64CrossRefGoogle Scholar
  41. 41.
    Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA et al (2009) A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 113(20):4903–4913CrossRefGoogle Scholar
  42. 42.
    Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur DS et al (2016) Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. Blood 127(3):352–359CrossRefGoogle Scholar
  43. 43.
    Seidl C (2014) Radioimmunotherapy with α-particle-emitting radionuclides. Immunotherapy 6(4):431–458CrossRefGoogle Scholar
  44. 44.
    Gokhale AS, Mayadev J, Pohlman B, Macklis RM (2005) Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 63(1):194–201CrossRefGoogle Scholar
  45. 45.
    Rajguru S, Kristinsdottir T, Eickhoff J, Peterson C, Meyer CM, Traynor AM et al (2014) Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Clin Adv Hematol Oncol 12(8):509–515Google Scholar
  46. 46.
    Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C et al (2014) Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol 164(5):710–716CrossRefGoogle Scholar
  47. 47.
    Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW et al (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109(9):1804–1810CrossRefGoogle Scholar
  48. 48.
    Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R et al (2016) Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol 173(2):274–282CrossRefGoogle Scholar
  49. 49.
    Trotman J, Barrington SF, Meignan M (2019) Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? Authors’ reply. PET investigators from the GALLIUM study. Lancet Oncol 20(1):e5CrossRefGoogle Scholar

Copyright information

© Italian Association of Nuclear Medicine and Molecular Imaging 2019

Authors and Affiliations

  • Silvia Morbelli
    • 1
    • 2
    Email author
  • Selene Capitanio
    • 1
    • 2
  • Luca Guerra
    • 3
  • Luigi Rigacci
    • 4
  1. 1.Nuclear Medicine UnitIRCCS Ospedale Policlinico San MartinoGenoaItaly
  2. 2.Nuclear Medicine Unit, Department of Health SciencesUniversity of GenoaGenoaItaly
  3. 3.Nuclear Medicine UnitSan Gerardo HospitalMonzaItaly
  4. 4.UO Ematologia e Centro Trapianti Cellule Staminali, AO San Camillo ForlaniniRomeItaly

Personalised recommendations